There's A Gap In Brain Tumor Research — Here's How We Fix It
By Catherine Bladen, Ph.D., tenured biochemistry researcher and scientist
As a cancer researcher, I have spent my career working to deepen our mechanistic understanding of the disease and inform novel treatment strategies. Like many in this field, I have been encouraged by the significant advances oncology has achieved over the past 20 years. The emergence of biologics, targeted therapies, and precision medicine approaches has transformed outcomes across multiple tumor types and reshaped expectations for what is possible in cancer care.
Several months ago, my perspective shifted in a way that no amount of scientific training could fully prepare me for. At the age of 78, my mother was diagnosed with glioblastoma and given only months to live. The scientific challenges I had long considered from a more abstract, professional standpoint became deeply personal. With that shift came a stark realization: Despite the massive progress seen in other areas of oncology, brain tumors remain among the most biologically complex and least improved indications in terms of therapeutic outcomes.
A Persistent Innovation Gap
Across oncology, advances in molecular profiling and targeted therapy development have enabled increasingly precise intervention strategies. In contrast, the standard of care for glioblastoma has remained largely unchanged for decades. Surgical resection followed by radiation and temozolomide chemotherapy continues to be the dominant treatment option, with only modest incremental improvements in survival.
This disparity reflects a broader innovation gap. While many tumor types have benefited from advances in biomarker-driven drug development and immuno-oncology, brain tumors have proven far more resistant to these approaches. The result is a persistent disconnect between scientific capability and clinical impact in this indication.
One of the greatest drivers of this gap in brain tumor research is the degree of biological heterogeneity across the disease. Brain tumors encompass more than 100 distinct tumor types, each with unique molecular and clinical characteristics. Even within glioblastoma, intratumoral heterogeneity is pronounced, with multiple cellular subpopulations coexisting and evolving over time. This heterogeneity has significant implications for therapeutic development. Subclonal diversity enables rapid adaptation under therapeutic pressure, contributing to resistance and disease progression.
Despite this complexity, treatment strategies remain largely standardized across patients. A one-size-fits-all approach is woefully inadequate. Addressing this mismatch will require a shift toward more granular molecular characterization and patient stratification. Approaches that integrate genomic, transcriptomic, and proteomic data to define tumor-specific vulnerabilities will be essential to driving translational and clinical research. Precision medicine has demonstrated its value in other oncology settings but applying it effectively in brain tumors will require overcoming additional layers of complexity.
Navigating Unique Scientific Barriers
Brain tumors present several challenges that distinguish them from other cancers. The blood-brain barrier (BBB) remains a primary obstacle, limiting the penetration of many small molecules and biologics into the central nervous system. Even compounds with demonstrated activity in peripheral tumor models often fail to reach therapeutic concentrations in brain tissue. In addition, the tumor microenvironment (TME) within the brain differs substantially from that of other tissues. Interactions between tumor cells, glial cells, immune components, and the vasculature create a highly specialized and dynamic system that influences both disease progression and therapeutic response.
Emerging strategies are beginning to address these barriers. Engineered biologics, peptides, and antibody-based constructs are being developed with enhanced CNS penetration and target specificity. Alternative delivery strategies, including localized and intrathecal approaches, are also under investigation. However, these approaches remain in relatively early stages of development. Meaningful advancement will require continued investment in both fundamental biology and translational research, as well as improved models that more accurately capture the complexity of CNS tumors.
Expanding The Research Toolbox
Although clinical outcomes in brain tumors have lagged, the tools available to oncology researchers have advanced significantly. High-throughput sequencing, single-cell analysis, and spatial transcriptomics now enable detailed characterization of tumor heterogeneity and microenvironmental interactions. Advances in biologics and recombinant antibody engineering have expanded the range of targetable mechanisms. Cell-based therapies, such as CAR-T and other promising platforms, are being adapted for solid tumors. These approaches offer new opportunities but also introduce additional layers of complexity in development and translation to CNS indications.
The effectiveness of these innovations depends heavily on the underlying research infrastructure. High-quality reagents, robust in vitro and in vivo models, and reproducible analytical methods are essential for generating meaningful data. Understanding how therapeutic candidates interact with heterogeneous tumor cell populations and the CNS microenvironment requires precision at every stage of experimentation. Progress in this field will depend not only on the development of new therapeutic modalities but also on the continued evolution of the tools that enable their evaluation.
Moving Forward
For those of us working in basic research, it is easy to narrow our view of progress in cancer to understanding mechanisms at the level of cells and proteins. However, the impact of these efforts is ultimately measured at the patient level. Experiencing a glioblastoma diagnosis within my own family has reinforced the urgency of translating basic research advances to groundbreaking therapies. The limited treatment options, rapid disease progression, and uncertainty surrounding outcomes highlight the gap between current scientific capabilities and patient needs.
It also underscores the importance of aligning research priorities with clinical realities. Incremental advances are important, but for patients facing aggressive brain tumors, meaningful progress depends on improved survival and quality of life. Closing the innovation gap in brain tumor research will require coordinated efforts across multiple domains. Greater investment in CNS-specific biology, improved model systems, and more sophisticated approaches to drug delivery are all essential. Equally important is the integration of multidisciplinary expertise to address the complexity of these diseases.
Advancing toward more personalized therapeutic strategies will depend on deeper molecular understanding and the ability to translate that knowledge into actionable targets. At the same time, ensuring that the tools and technologies used in research can capture this complexity will be critical. The challenges are substantial, but the potential for impact is equally significant. With sustained focus and collaboration, it is possible to begin translating the broader advances in oncology into real-world progress for patients with brain tumors.
For patients like my mother, and for the many families navigating similar diagnoses, that progress cannot come soon enough.
About The Author:
Catherine Bladen, Ph.D., is a biochemistry researcher with more than 25 years of experience in cancer research, specializing in protein identification, purification, and characterization across both the U.K. and the U.S. She earned her Ph.D. from the Cancer Research Unit at Newcastle University, where her research focused on novel proteins involved in p53-independent cancer pathways. Catherine’s work has centered on advancing scientific understanding to support the development of new diagnostic and therapeutic approaches.